Vaccination campaigns against influenza, Covid-19 and pneumococcus for the 2024-2025 season have started. Dr Kierzek provides an update on the different vaccines and the people affected.
The vaccination campaign for the 2024-2025 season has started October 15 in mainland France and will end on January 31, 2025 with an end scheduled for January 31, 2025 for influenza. This campaign includes vaccination against influenza, COVID-19 and pneumococcus, with the possibility of receiving the vaccines simultaneously.
The different vaccines and their specificities
Every year it is necessary to renew vaccination against influenza and COVID-19 due to different strains and seasonally limited protection.
Flu vaccination
- It is recommended for people at risk: People aged 65 and over, pregnant women and people with chronic illnesses.
- Three vaccines available.
- 100% support for targeted populations.
- Objective of 75% vaccination coverage for populations at risk.
Vaccination against Covid-19
- Only one vaccine available (3 dosages depending on age).
- Recommended for people at risk of severe disease.
- 100% support for everyone.
- 6 month deadline after the last injection/infection.
These measures aim to protect vulnerable populations against these respiratory infections and limit their spread.
The importance of vaccination against pneumococcus
Vaccination against pneumococcusless known but essential, helps prevent pneumococcal pneumonia, a serious lung infection. It is recommended for:
- People aged 65 and over.
- People at increased risk (chronic diseases, immunosuppression).
The 2024-2025 campaign focuses on protecting vulnerable populations by facilitating access to vaccinations. Barrier gestures also remain important.
The advice of Dr. Gérald Kierzek
Join us every morning at 8:50 a.m. The advice of Dr. Kierzek. From managing our stress to our nutrition and even our sleep, he gives you good advice on every aspect of our daily life.
You can also find this column replayed on the HERE app and the Radio France app.
France
COVID-19